Soligenix, Inc. (SNGX) Stock

Soligenix, Inc. (SNGX) is a Healthcare stock trading at $0.42 (as of 2026-06-16), with a market capitalization of $8.49M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Soligenix, Inc. is a biopharmaceutical company developing and commercializing therapies for rare diseases in the United States through two segments: Specialized BioTherapeutics and Public Health Solutions. Its Specialized BioTherapeutics activities include SGX301 (HyBryte), SGX942, and additional therapeutic candidates and proprietary formulations, while Public Health Solutions focuses on products such as the ricin toxin vaccine candidate RiVax and a therapeutic candidate SGX943.

Understand Soligenix, Inc.: how it makes money

Soligenix develops and commercializes late-stage biopharmaceutical treatments for rare diseases in the United States, aiming to turn its Phase III clinical programs into approved, revenue-generating therapies (including SGX301 HyBryte for cutaneous T-cell lymphoma and SGX942 for inflammatory diseases).

The core profit engine is clinical progress through its two Phase III programs, because any future commercial revenue depends on successfully completing confirmatory evidence for SGX301 (HyBryte) and SGX942 and then obtaining approval for use in the United States.

Business quality (Weak): Quality is driven by late-stage clinical execution and outcomes, while current financials show no meaningful revenue yet.

Bull case

  • HyBryte has completed a Phase III clinical trial for the treatment of cutaneous T-cell lymphoma: This supports that the company has reached late-stage validation for one lead asset (SGX301, HyBryte).
  • Ongoing Phase 3 FLASH2 confirmatory trial has enrolled 169.0 patients: Enrollment progress can be a leading indicator of the ability to generate additional confirmatory evidence.

Bear case

  • No reported revenue in the latest quarter provided (2024-09-30 revenue_b is 0.0): Financial impact is not yet visible in reported top-line results.
  • Operating margin is highly negative in the latest quarter provided (operating_margin_pct is -1562.6): Costs are far exceeding operating contribution, typical of pre-commercial or early commercialization stages.
  • SGX942 is still in Phase III for inflammatory diseases, including oral mucositis in head a: Even with late-stage status, approvals and commercial outcomes are not guaranteed for the full pipeline.
Valuation — source: SEC EDGAR (first-party)
Price$0.42
Market Cap$8.49M
Price / Book1.28
Price / Sales71.11
FCF Yield-114.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$119371.00
Net Margin-6925.1%
Return on Equity-154.1%
Current Ratio2.77
Revenue Growth (YoY)-85.8%
EPS Growth (YoY)530.4%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderGEODE CAPITAL MANAGEMENT, LLC ($141915.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOChristopher J. Schaber
Employees14
CountryUS
IPO Date1994-04-04

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Adial Pharmaceuticals, Inc. (ADIL)
  • Imunon, Inc. (IMNN)
  • Traws Pharma, Inc. (TRAW)
  • CNS Pharmaceuticals, Inc. (CNSP)
  • GeoVax Labs, Inc. (GOVX)
  • Exicure, Inc. (XCUR)
  • Azitra, Inc. (AZTR)
  • Kairos Pharma, Ltd. (KAPA)
SNGX earnings history · SNGX institutional & insider holders · SNGX KPIs & operating metrics · SNGX financials · SNGX investor presentations & press releases · SNGX SEC filings · SNGX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-16.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.